Researchers are zeroing in on understanding what goes awry in the brains of people with Alzheimer’s disease.
Tek Image/Science Photo Library via Getty Images
Despite decades of starts and stops, new treatments and key genetic discoveries are giving researchers great hope for slowing or eventually preventing Alzheimer’s disease.
Alzheimer’s disease is an incapacitating, progressive brain disorder that affects the lives of more than 6.5 million Americans.
PamelaJoeMcFarlane/E+ via Getty Images
In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
Two new dementia drugs are being hailed as breakthroughs. But what might be an incremental breakthrough for researchers, doesn’t mean a cure for patients.
A new theory of Alzheimer’s disease reassesses the role of beta-amyloid in the brain.
(AP Photo/Evan Vucci)
Alzheimer’s may not be primarily a disease of the brain. It may be a disorder of the immune system within the brain. Beta-amyloid may not be an abnormal protein, but part of the brain’s immune system.
An illustration of amyloid plaques within the human brain, characteristic features of Alzheimer’s. By 2060, approximately 14 million Americans are expected to have the disease.
Kateryna Kon/Science Photo Library via Getty Images
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
Alzheimer’s disease is characterized by progressive memory loss, spatial disorientation and many other cognitive and behavioural disorders that ultimately lead to a state of total dependence.
(Shutterstock)
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.